arGEN-X Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | arGEN-X

arGEN-X N.V. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

6,230.00

10,743.00

15,605.00

21,416.00

22,932.00

81,849

Depreciation, Depletion & Amortization

121.00

132.00

196.00

334.00

435.00

493

Other Funds

427.00

1,086.00

2,382.00

2,923.00

4,677.00

19,971

Funds from Operations

5,682.00

9,525.00

13,027.00

18,159.00

17,820.00

61,385

Changes in Working Capital

188.00

4,427.00

758.00

28,831.00

18,351.00

8,917

Net Operating Cash Flow

5,870.00

5,098.00

13,785.00

10,672.00

36,171.00

52,468

Capital Expenditures

65.00

185.00

279.00

861.00

351.00

Purchase/Sale of Investments

16,979.00

18.00

162,076.00

Net Investing Cash Flow

65.00

23,478.00

16,700.00

879.00

162,427.00

Net Financing Cash Flow

13,308.00

37,741.00

238.00

44,621.00

305,365.00

Net Change in Cash

7,290.00

9,460.00

3,334.00

54,383.00

100,970.00

Free Cash Flow

5,935.00

5,272.00

14,059.00

9,832.00

36,516.00

Change in Capital Stock

13,308.00

37,741.00

238.00

44,621.00

305,365.00

Exchange Rate Effect

83.00

295.00

181.00

31.00

5,797.00

Other Uses

23,293.00

About arGEN-X

View Profile

Address	Willemstraat 5 Breda Noord-Brabant 4811 AH Netherlands
Employees	-
Website	http://www.argen-x.com
Updated	07/08/2019
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia. It operates through the following geographical segments: Netherlands, Belgium, Germany, Denmark, Switzerland, United States, and Luxemburg.